Below are the financial statements of BeOne Medicines, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 as of 2024-12-31 | 2023 as of 2023-12-31 |
|---|---|---|
| Assets | — | — |
| Current assets | — | — |
| Cash and cash equivalents | 2,627.41a | 3,171.8a |
| Accounts receivable, net | 676.28a | 358.03a |
| Inventories, net | 494.99a | 416.12a |
| Prepaid expenses and other current assets | 192.92a | 257.47a |
| Total current assets | 3,991.59a | 4,203.41a |
| Property, plant and equipment, net | 1,578.42a | 1,324.15a |
| Operating lease right-of-use assets | 139.31a | 95.21a |
| Intangible assets, net | 51.1a | 57.14a |
| Other non-current assets | 160.49a | 125.36a |
| Total non-current assets | 1,929.32a | 1,601.86a |
| Total assets | 5,920.91a | 5,805.28a |
| Liabilities and shareholders’ equity | — | — |
| Current liabilities | — | — |
| Accounts payable | 405a | 315.11a |
| Accrued expenses and other payables | 803.71a | 693.73a |
| Tax payable | 25.93a | 22.95a |
| Operating lease liabilities, current portion | 17.58a | 21.95a |
| Research and development cost share liability, current portion | 111.15a | 68a |
| Short-term debt | 851.53a | 688.37a |
| Total current liabilities | 2,214.9a | 1,810.11a |
| Non-current liabilities | — | — |
| Long-term debt | 166.48a | 197.62a |
| Operating lease liabilities, non-current portion | 44.28a | 22.25a |
| Deferred tax liabilities | 42.01a | 16.49a |
| Research and development cost share liability, non-current portion | 54.29a | 170.66a |
| Other long-term liabilities | 66.74a | 50.81a |
| Total non-current liabilities | 373.79a | 457.84a |
| Total liabilities | 2,588.69a | 2,267.95a |
| Shareholders’ equity | — | — |
| Ordinary shares | 0.14a | 0.14a |
| Additional paid-in capital | 12,087.91a | 11,598.69a |
| Accumulated other comprehensive loss | -148.99a | -99.45a |
| Accumulated deficit | -8,606.84a | -7,962.05a |
| Total shareholders’ equity | 3,332.22a | 3,537.33a |
| Total liabilities and shareholders’ equity | 5,920.91a | 5,805.28a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.